TriangleNCT03848182 · OUTCOME
Change in Myeloid-derived Suppressor Cells
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Day 8
Analysis population: MDSC data was not collected or analyzed for this study.
Groups in this outcome
Gemcitabine With TT Vaccine Booster
Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT Gemcitabine: Gemcitabine will be administered on days 1, 8, 15 every 28 days TT vaccine booster: One human TT childhood vaccine booster will be administered on day 8
| Group | Source count |
|---|---|
| Gemcitabine With TT Vaccine Booster | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- groups
- description
- Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT Gemcitabine: Gemcitabine will be administered on days 1, 8, 15 every 28 days TT vaccine booster: One human TT childhood vaccine booster will be administered on day 8
- id
- OG000
- title
- Gemcitabine With TT Vaccine Booster
- population Description
- MDSC data was not collected or analyzed for this study.
- reporting Status
- POSTED
- time Frame
- Day 8
- title
- Change in Myeloid-derived Suppressor Cells
- type
- OTHER_PRE_SPECIFIED
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice